Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Stilbenes in food and medicinal plants have been described as potent antiphlogistic and antioxidant compounds, and therefore, they present an interesting potential for the development of dietary supplements. Among them, macasiamenene F (MF) has recently been shown to be an effective anti-inflammatory and cytoprotective agent that dampens peripheral and CNS inflammation . Nevertheless, this promising molecule, like other stilbenes and a large percentage of drugs under development, faces poor water solubility, which results in trickier administration and low bioavailability. With the aim of improving MF solubility and developing a form optimized for administration, eight types of conventional liposomal nanocarriers and one type of PEGylated liposomes were formulated and characterized. In order to select the appropriate form of MF encapsulation, the safety of MF liposomal formulations was evaluated on THP-1 and THP-1-XBlue-MD2-CD14 monocytes, BV-2 microglia, and primary cortical neurons in culture. Furthermore, the cellular uptake of liposomes and the effect of encapsulation on MF anti-inflammatory effectiveness were evaluated on THP-1-XBlue-MD2-CD14 monocytes and BV-2 microglia. MF (5 mol %) encapsulated in PEGylated liposomes with an average size of 160 nm and polydispersity index of 0.122 was stable, safe, and the most promising form of MF encapsulation keeping its cytoprotective and anti-inflammatory properties.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10905713PMC
http://dx.doi.org/10.1021/acsomega.3c07380DOI Listing

Publication Analysis

Top Keywords

pegylated liposomes
8
form encapsulation
8
thp-1-xblue-md2-cd14 monocytes
8
monocytes bv-2
8
bv-2 microglia
8
enhancing solubility
4
solubility bioefficacy
4
bioefficacy stilbenes
4
stilbenes liposomal
4
liposomal encapsulation-the
4

Similar Publications

Objectives: To evaluate the association between the KRAS mutational load and the histologic tumor response in patients with resectable pancreatic ductal adenocarcinoma (PDAC) who received neoadjuvant treatment (NAC) with pegylated liposomal irinotecan in combination with oxaliplatin, 5-fluorouracil, and leucovorin (NALIRIFOX).

Methods: This was a multicenter, single-arm, interventional, open-label, phase 2 trial in patients 18 years or older who had histologically or cytologically confirmed PDAC and were candidates for surgery and received neoadjuvant NALIRIFOX. The primary outcome was determination of the association between the KRAS mutational load and the histologic tumor response after chemotherapy.

View Article and Find Full Text PDF

Purpose: Breast cancer is the leading cause of cancer-related deaths among women. Chemotherapy faces challenges such as systemic toxicity and multidrug resistance. Advances in nanotechnology have led researchers to develop safer and more efficient cancer treatment methods.

View Article and Find Full Text PDF

Cancer treatment faces challenges like nonselective toxicity and drug resistance, prompting the need for innovative therapies. This study aimed to develop liposomal formulations for co-delivery of empagliflozin and rutin, evaluating their anticancer and antioxidant efficacy. PEGylated empagliflozin-loaded nanoliposomes (Empa-NLs) and empagliflozin-rutin co-loaded nanoliposomes (Empa-Rut NLs) were synthesized using the thin-film hydration technique.

View Article and Find Full Text PDF

Lactation-associated breast cancer poses diagnostic challenges due to physiological breast changes that may mask malignancies. Triple-negative breast cancer (TNBC) during lactation is rare and aggressive, requiring vigilant evaluation and treatment. This report highlights the diagnostic dilemma of recurrent cystic breast lesions during lactation, which can mimic benign conditions like galactoceles but may conceal aggressive TNBC, leading to potential delays in diagnosis despite initial conservative approaches such as aspiration.

View Article and Find Full Text PDF

The prevalence of anti-polyethylene glycol (PEG) antibodies poses a significant challenge for the clinical translation of PEGylated liposomes, leading to an accelerated blood clearance (ABC) phenomenon and diminishing therapeutic effectiveness. To address this limitation, we designed an asymmetrical branched PEG derivative (mPEG-DSPE) and prepared mPEG-DSPE-modified liposomes, which included 1,1'-dioctadecyl-3,3,3,3'-tetramethylindo dicarbocyanine iodide liposomes (P-DiR) and mitomycin C lipid prodrug (MSC) liposomes (P-MSC) to minimize the binding of anti-PEG antibodies. Cellular binding assays revealed that the anti-PEG antibody binding rate for P-DiR was only 0.

View Article and Find Full Text PDF